Evaxion Biotech AS

Evaxion A/S is a clinical-stage biotechnology company that develops AI-powered immunology vaccines. Its pipeline includes EVX-01, in a phase 2 global multi-center trial for advanced melanoma; EVX-03, a DNA-based cancer vaccine for solid tumors; and EVX-04, a therapeutic cancer vaccine candidate in phase 1 for acute myeloid leukemia. Pre-clinical programs include EVX-B1 for skin and soft tissue infections caused by S. aureus, EVX-B2 for gonorrhea, EVX-B3 for a bacterial pathogen associated with repeated infections, and EVX-V1 for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Incorporated in 2008, it is based in Horsholm, Denmark.